News - Valeant Pharmaceuticals, Dysport


Popular Filters

1 to 25 of 57 results

Valeant Pharma returns to profit, boosted by B&L acquisition


Canadian drugmaker Valeant Pharmaceuticals International has announces fourth quarter financial results…

Bausch & LombFinancialGenericsValeant Pharmaceuticals

Ipsen’s Dysport next generation shows safety and efficacy in Phase III

Ipsen’s Dysport next generation shows safety and efficacy in Phase III


French drugmaker Ipsen today announced the results of the international Phase III clinical trial of Dysport…


Valeant spending $475 million to boost dermatology portfolio

Valeant spending $475 million to boost dermatology portfolio


Acquisitive Canadian drugmaker Valeant Pharmaceuticals International has entered into a definitive agreement…

DermatologicalsMergers & AcquisitionsPharmaceuticalPreCision DermatologyValeant Pharmaceuticals

Patent settlements for Pfizer/Teva and Mylan/Eisai

Patent settlements for Pfizer/Teva and Mylan/Eisai


US pharma behemoth Pfizer says it has settled its long-standing litigation against a US subsidiary of…

Banner PharmacapsEisaiGenericsLegalMen's HealthMylan LaboratoriesNorth AmericaOncologyPatentsPfizerTargretinTeva Pharmaceutical IndustriesValeant PharmaceuticalsViagra

Ipsen reports positive Phase III results for Dysport in adult upper limb spasticity

Ipsen reports positive Phase III results for Dysport in adult upper limb spasticity


French drugmaker Ipsen (Euronext: IPN) has announced positive initial results from a Phase III study…

DysportIpsenNeurologicalNorthern EuropePharmaceuticalResearch

Valeant agrees $142.5 million settlement with Anacor


Anacor Pharmaceuticals says it has entered into a $142,5 million settlement agreement with Canada-based…

Anacor PharmaceuticalsFinancialLegalNorth AmericaPharmaceuticalValeant Pharmaceuticals

Anacor Pharma awarded $100 million damages


Anacor Pharmaceuticals says that the arbitrator appointed to resolve its dispute with Canada-based Valeant…

Anacor PharmaceuticalsLegalNorth AmericaPharmaceuticalValeant Pharmaceuticals

Valeant Pharma beats forecasts, turns in profit


Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) announced second quarter financial…

Bausch & LombFinancialGenericsValeant Pharmaceuticals

Valeant confirms plan to acquire Bausch & Lomb in a $8.7 billion transaction


Following speculation ahead of the extended holiday weekend, acquisitive Canadian drugmaker Valeant Pharmaceuticals…

Bausch & LombMergers & AcquisitionsOphthalmicsPharmaceuticalValeant Pharmaceuticals

Actavis and Valeant report first quarter 2013 results


US generics drug major Actavis (NYSE: ACT) and Canada's Valeant Pharmaceuticals (TSX: VRX) both presented…

ActavisFinancialGenericsValeant Pharmaceuticals

Actavis in OxyContin patent settlement; Valeant takeover bid "on hold"?


US generic major Actavis (NYSE: ACT) has entered into an agreement with privately-held Purdue Pharma…

ActavisGenericsMergers & AcquisitionsNeurologicalNorth AmericaOxyContinPatentsPurdue PharmaValeant Pharmaceuticals

Actavis settles with Valeant to launch generic Ziana and Zyclara in USA


US generics drug major Actavis (NYSE: ACT) has reached settlement agreements with Medicis Pharmaceutical,…

ActavisGenericsMarkets & MarketingNorth AmericaPatentsValeant PharmaceuticalsZiana GelZyclara

Actavis and Valeant to co-promote Zovirax and Cordran Tape


Valeant Pharmaceuticals International (TSX: VRX) entered into an agreement, effective immediately, for…

ActavisAnti-viralsCordran TapeGenericsLicensingMarkets & MarketingMylan LaboratoriesNorth AmericaValeant PharmaceuticalsZovirax Ointment

Merz Pharma enters bidding war for Obagi; Ferro sells pharma unit


German family-owned firm Merz Pharma has written to the board of director of Obagi Medical Products outlining…

Ferro GroupGenericsMergers & AcquisitionsMerz PharmaceuticalsObagi Medical ProductsPfanstiehl LaboratoriesPharmaceuticalValeant Pharmaceuticals

Valeant to acquire Obagi Medical for around $344 million


Canada-based Valeant Pharmaceuticals International (TSX: VRX) is on the acquisition trail again, announcing…

DermatologicalsMergers & AcquisitionsObagi Medical ProductsPharmaceuticalValeant Pharmaceuticals

Valeant Pharma buys US rights to Eisai's Targretin for $65 million upfront


Canada's Valeant Pharmaceuticals International (TSX: VRX) says that it has acquired US rights for Targretin…

EisaiLicensingNorth AmericaOncologyPharmaceuticalTargretinValeant Pharmaceuticals

News briefs from Bayer, AstraZeneca and Valeant/Galderma


German drug major Bayer (BAYN: DE) and partner Regeneron (Nasdaq: REGN) submitted a marketing application…

AstraZenecaBayerEuropeEyleaFaslodexGaldermaLicensingNorth AmericaOncologyOphthalmicsPerlanePharmaceuticalRegulationRestylaneValeant Pharmaceuticals

News briefs on Ipsen/Galderma and YM BioSciences nimotuzumab assets


French drugmaker Ipsen (Euronext: IPN) and Switzerland-headquartered Galderma have expanded their collaboration…

Asia-PacificBiotechnologyCIMABDysportGaldermaInnoKeys PTEIpsenLicensingnimotuzumabOncologyPharmaceuticalSouth AmericaYM Biosciences

1 to 25 of 57 results

Company Spotlight



Back to top